Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Full Archive
Empyema Challenges After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is very tough to treat. Surgery is one part of multimodal therapy that aims to remove as much cancer as possible. Surgery is a very useful tool in the treatment of mesothelioma, but after surgery, complications can occur. One complication can be[…]
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NECIM)
Primary Outcome Measures To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma. Secondary Outcome Measures Toxicity of the neoadjuvant double chemotherapy / double immunotherapy regimen and[…]
Advances in Immunotherapy for Mesothelioma
Malignant mesothelioma is a very rare cancer that often has a poor outlook in cancer treatment. Immunotherapy, especially in the form of immune checkpoint inhibitors, has brought hope. It shows the potential for better outcomes in mesothelioma patients. A new article in Open Respiratory Archives provides a history of recent[…]
Carcinogenicity of Forsterite Compared to Asbestos
Mesothelioma, a rare cancer caused by asbestos, continues to be a global health issue. The most common form of asbestos is chrysotile. Recent research looked at chrysotile and a heat-treated form called forsterite. This research can help with safer asbestos disposal in the future. A recent study examined whether forsterite,[…]
New Clinical Trial is Testing CAR-T Cell Therapy for Mesothelioma and Other Hard to Treat Tumors
A new clinical trial that launched this month is testing a new immunotherapy regimen that could offer hope to people with mesothelioma and other hard to treat cancers. It will be examining an experimental treatment that utilizes CAR-T cells, an immune cell engineered to find and attack cancer cells. The[…]
An International Study on Pediatric Patients With Rare Tumors. (PARTNER)
Primary Outcome Measures Epidemiology Use of International Recommendations Survival of children and adolescents (0-18 years) affected by Very Rare Tumors Inclusion Criteria Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. Written informed consent from the patient and/or[…]
Immunotherapy Benefits and Drawbacks for Treating Mesothelioma
Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
Genetic Testing for Mesothelioma
Mesothelioma is a serious cancer that affects the lining of certain organs and body cavities. It mainly affects older adults, but it can affect people of all ages. It is rare in children, but pediatric mesothelioma is still possible. A recent study looked at pediatric peritoneal mesothelioma. The study highlights[…]
MARS 2 Trial for Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that is linked to asbestos exposure. It affects the lining of the lungs. Every year, there are over 2,500 people in the United Kingdom that are diagnosed with the cancer. A study known as MARS 2 investigated if adding surgery to chemotherapy[…]
Skip to content